相似文献
1
Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
Vaccine. 2017 Oct 13;35(43):5756-5758. doi: 10.1016/j.vaccine.2017.09.009. Epub 2017 Sep 19.
2
No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
Vaccine. 2017 Mar 23;35(13):1729-1732. doi: 10.1016/j.vaccine.2017.01.076. Epub 2017 Feb 27.
3
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21.
4
Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.
Am J Epidemiol. 2012 Jun 1;175(11):1100-9. doi: 10.1093/aje/kws195. Epub 2012 May 11.
5
Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.
Hum Vaccin Immunother. 2014;10(1):232-7. doi: 10.4161/hv.26292. Epub 2013 Sep 6.
6
Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.
Am J Epidemiol. 2012 Jun 1;175(11):1110-9. doi: 10.1093/aje/kws196. Epub 2012 May 11.
7
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
JAMA Netw Open. 2022 Apr 1;5(4):e228879. doi: 10.1001/jamanetworkopen.2022.8879.
8
Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2073750. doi: 10.1080/21645515.2022.2073750. Epub 2022 Jun 17.
9
The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
Vaccine. 2020 Nov 3;38(47):7458-7463. doi: 10.1016/j.vaccine.2020.09.072. Epub 2020 Oct 7.
10
Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
Vaccine. 2021 Jul 13;39(31):4306-4313. doi: 10.1016/j.vaccine.2021.06.029. Epub 2021 Jun 24.
引用本文的文献
1
Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports.
Hum Vaccin Immunother. 2025 Dec;21(1):2539590. doi: 10.1080/21645515.2025.2539590. Epub 2025 Aug 1.
2
Human papillomavirus nonavalent (HPV9) vaccination and risk of immune mediated diseases, myocarditis, pericarditis, and thromboembolic outcomes in Denmark: self-controlled case series study.
BMJ Med. 2024 Oct 22;3(1):e000854. doi: 10.1136/bmjmed-2024-000854. eCollection 2024.
3
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.
Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022.
4
Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020.
Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2001619.
5
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
Hum Vaccin Immunother. 2021 Dec 2;17(12):5447-5453. doi: 10.1080/21645515.2021.1978793. Epub 2021 Oct 6.
6
Vaccinations and Autoimmune Diseases.
Vaccines (Basel). 2021 Jul 22;9(8):815. doi: 10.3390/vaccines9080815.
7
Vaccine safety issues at the turn of the 21st century.
BMJ Glob Health. 2021 May;6(Suppl 2). doi: 10.1136/bmjgh-2020-004898.
8
Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data.
J Korean Med Sci. 2021 Mar 8;36(9):e67. doi: 10.3346/jkms.2021.36.e67.
9
The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
Vaccine. 2020 Nov 3;38(47):7458-7463. doi: 10.1016/j.vaccine.2020.09.072. Epub 2020 Oct 7.
10
Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016).
Rev Inst Med Trop Sao Paulo. 2019 Sep 12;61:e43. doi: 10.1590/S1678-9946201961043.
本文引用的文献
1
Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Vaccine. 2017 Aug 24;35(36):4761-4768. doi: 10.1016/j.vaccine.2017.06.030. Epub 2017 Jul 24.
2
No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
Vaccine. 2017 Mar 23;35(13):1729-1732. doi: 10.1016/j.vaccine.2017.01.076. Epub 2017 Feb 27.
3
Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4.
4
Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic.
Am J Public Health. 2014 Apr;104(4):696-701. doi: 10.2105/AJPH.2013.301651. Epub 2014 Feb 13.
5
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
J Intern Med. 2014 Apr;275(4):398-408. doi: 10.1111/joim.12155. Epub 2013 Nov 22.
6
Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.
BMJ. 2013 Oct 9;347:f5906. doi: 10.1136/bmj.f5906.
7
Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.
PLoS One. 2013 Jun 26;8(6):e67185. doi: 10.1371/journal.pone.0067185. Print 2013.
8
Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
Lancet. 2013 Apr 27;381(9876):1461-8. doi: 10.1016/S0140-6736(12)62189-8. Epub 2013 Mar 13.
9
No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies.
Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1359-60. doi: 10.1002/pds.3353.
10
Guillain-Barré syndrome incidence in a large United States cohort (2000-2009).
Neuroepidemiology. 2012;39(2):109-15. doi: 10.1159/000339248. Epub 2012 Jul 28.
Zotero 插件